Company Overview

Theralase® was one of the first companies in North America to bring CLT to patients and the first company in the world to bring personalized ACT to patients individual tissue characteristics. 

With our multi-discipline experience in physics, engineering, medicine, biology, chemistry, immunology, pharmaceutical drug design, finance, business development, sales, marketing and clinical study coordination, Theralase® is staffed with the talent to drive the next level of technology for personalized healthcare in oncology and pain. 

Striving to continuously improve the quality of life for those afflicted with cancer and pain. Theralase®’s research, development and commercialization activities focus on safely and effectively treating oncological and pain-related conditions. Serving our corporate mandate to “Destroying Cancer at the Speed of Light®” and “Healing Pain at the Speed of Light®”.   

Founded in 1994, Theralase®’s operations are divided into two main divisions: the Cool Laser Therapy (“CLT”) division focused on the research, development, production and distribution of medical laser technologies for healing pain and also researching, developing and commercializing medical laser technologies for the activation of Photo Dynamic Compounds (“PDCs”) in the Anti-Cancer Therapy (“ACT”) division and the ACT division focused on the destruction of cancer, bacteria and viruses.